Biocon Ltd banner

Intrinsic Value

The intrinsic value of Biocon Ltd (BIOCON) under the Base Case is 369.35 INR per share. Compared with the current market price of 364.4 INR, the stock appears Undervalued by 1% .

The intrinsic value is calculated using the DCF method. The model assumes net margin rises from 2.3% last year to 8.1% by 2042, above its five-year average of 5.6%. Revenue grows about 13% a year over the next five years, below its five-year pace of 19%. The value of the years after 2042 is tied to revenue, so margins count only until then.

Do our valuations actually work? See backtest results .

BIOCON Intrinsic Value
₹369.35
Undervaluation 1%
Intrinsic Value
Price ₹364.4

BIOCON is valued in line with its history. A discount of this size has been typical over the past 5 years.

Alert me when BIOCON is below its intrinsic value
Today ₹295.48 · 18.9% below the current price
Alternatives to BIOCON

Fundamental Analysis

What Biocon Does

Biotechnology Health Care

Biocon Ltd is a biopharmaceutical company that develops and makes medicines for diabetes, cancer, and other long-term illnesses. It sells a mix of biologic drugs, biosimilars, generic formulations, and key ingredients used by other drug makers. The company also works in contract research and development through its services businesses, which support drug discovery and testing for other pharmaceutical firms.

Headquarters
India IN
Employees
16 420
IPO date
Apr 17, 2004
Read the full company overview
View Company Overview

Biocon has a narrow economic moat

No Moat Narrow Wide

Biocon Ltd has a narrow economic moat, offering limited protection against competitors and some ability to sustain profitability.

Read the full moat analysis
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q2 fiscal 2027 · November 4, 2026

Biocon framed the second half as an execution inflection, with biosimilar momentum, improving generics profitability and a recovering Syngene trajectory supporting commercial acceleration.

Open the earnings call
EPS
₹0.29
Expected
₹1.04
Surprise
−72.1%
Stock, day of the call
+0.4%
View Earnings Call

Past 12 months

Continue BIOCON Research

Decided on Biocon? Get an email when BIOCON reaches the price you’d buy at. Free with an account.

Other Biocon listings

What is the Intrinsic Value of one BIOCON stock?

The intrinsic value for Biocon Ltd (BIOCON) under the Base Case is 369.35 INR.

Is BIOCON stock undervalued or overvalued?

Compared with the current market price of 364.4 INR, the stock appears Undervalued by 1% .

How reliable are our estimates? See how past valuations played out
Back to Top